Although most SARS-CoV-2-infected individuals experience mild coronavirus disease 2019 (COVID-19), some patients suffer from severe COVID-19, which is accompanied by acute respiratory distress syndrome and systemic inflammation. To identify factors driving severe progression of COVID-19, we performed single-cell RNA-seq using peripheral blood mononuclear cells (PBMCs) obtained from healthy donors, patients with mild or severe COVID-19, and patients with severe influenza. Patients with COVID-19 exhibited hyper-inflammatory signatures across all types of cells among PBMCs, particularly up-regulation of the TNF/IL-1 beta-driven inflammatory response as compared to severe influenza. In classical monocytes from patients with severe COVID-19, typ...
Although infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has pleiotropic...
Coronavirus Disease 2019 (COVID-19) is a mild to moderate respiratory tract infection, however, a su...
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with ...
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with ...
In coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (S...
SARS-CoV-2 fine-tunes the interferon (IFN)-induced antiviral responses, which play a key role in pre...
Severe COVID-19 causes profound immune perturbations, but pre-infection immune signatures contributi...
Innate immune interferons (IFNs), including type I and III IFNs, constitute critical antiviral mecha...
We pursued a study of immune responses in coronavirus disease 2019 (COVID-19) and influenza patients...
Host immunity to infection with SARS-CoV-2 is highly variable, dictating diverse clinical outcomes r...
Antiviral type I interferons (IFN) produced in the early phase of viral infections effectively inhib...
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with ...
Understanding key host protective mechanisms against SARS-CoV-2 infection can help improve treatment...
The interferon pathway, a key antiviral defense mechanism, is being considered as a therapeutic targ...
Although infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has pleiotropic...
Coronavirus Disease 2019 (COVID-19) is a mild to moderate respiratory tract infection, however, a su...
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with ...
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with ...
In coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (S...
SARS-CoV-2 fine-tunes the interferon (IFN)-induced antiviral responses, which play a key role in pre...
Severe COVID-19 causes profound immune perturbations, but pre-infection immune signatures contributi...
Innate immune interferons (IFNs), including type I and III IFNs, constitute critical antiviral mecha...
We pursued a study of immune responses in coronavirus disease 2019 (COVID-19) and influenza patients...
Host immunity to infection with SARS-CoV-2 is highly variable, dictating diverse clinical outcomes r...
Antiviral type I interferons (IFN) produced in the early phase of viral infections effectively inhib...
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with ...
Understanding key host protective mechanisms against SARS-CoV-2 infection can help improve treatment...
The interferon pathway, a key antiviral defense mechanism, is being considered as a therapeutic targ...
Although infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has pleiotropic...
Coronavirus Disease 2019 (COVID-19) is a mild to moderate respiratory tract infection, however, a su...
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with ...